Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05453825
Title A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors OncXerna Theraputics, Inc.
Indications

ovary epithelial cancer

peritoneum cancer

stomach cancer

fallopian tube cancer

rectum adenocarcinoma

colorectal cancer

colon adenocarcinoma

gastroesophageal junction adenocarcinoma

triple-receptor negative breast cancer

Therapies

Irinotecan + Navicixizumab

Navicixizumab

Navicixizumab + Paclitaxel

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.